Skip to content
10-Q

Quarterly Report

ABVC BioPharma, Inc. ABVC

0001213900-26-058104

← back to feed
Filed
May 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 26M sh
Shares Diluted Q1 2026 · Mar 31, 2026 25.45M sh
Shares Diluted Q1 2026 · Mar 31, 2025 14.97M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$894.24K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$539.83K
Short Term Debt Q1 2026 · Mar 31, 2026 $88.74K
Short Term Debt Q1 2026 · Dec 31, 2025 $755.51K
Short Term Investments Q1 2026 · Mar 31, 2026 $62.19K
Short Term Investments Q1 2026 · Dec 31, 2025 $64.35K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $140.32K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $681.48K
Stockholders Equity Q1 2026 · Mar 31, 2026 $10.77M
Stockholders Equity Q1 2026 · Dec 31, 2025 $11.11M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.39M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.16M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.9M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.76M
Current Assets Q1 2026 · Mar 31, 2026 $648.85K
Current Assets Q1 2026 · Dec 31, 2025 $2.5M
Total Assets Q1 2026 · Mar 31, 2026 $19.73M
Total Assets Q1 2026 · Dec 31, 2025 $21.06M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.06
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.06
Eps Basic Q1 2026 · Mar 31, 2026 −$0.06
Eps Basic Q1 2026 · Mar 31, 2025 −$0.06
Sga Expense Q1 2026 · Mar 31, 2026 $752K
Sga Expense Q1 2026 · Mar 31, 2025 $615.37K
Rd Expense Q1 2026 · Mar 31, 2026 $33.1K
Rd Expense Q1 2026 · Mar 31, 2025 $28.86K
Net Income Q1 2026 · Mar 31, 2026 −$1.56M
Net Income Q1 2026 · Mar 31, 2025 −$842.08K
Operating Income Q1 2026 · Mar 31, 2026 −$1.57M
Operating Income Q1 2026 · Mar 31, 2025 −$693.01K